🔗 Share this article

Given that America proceeds with historic changes to its immunization recommendations, a particular individual has surfaced in a surprising turn: Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by questioning COVID-19 vaccines throughout the pandemic and has zeroed in on possible deaths following COVID-19 vaccination in her brief time at the Food and Drug Administration.

Scheduled Changes to Pediatric Immunization Schedule

Public health authorities were set to reveal sweeping changes to the pediatric vaccine schedule earlier this month, synchronizing the US with the Danish immunization schedule, it is understood – a substantial departure that would put the US at odds with many the world with no evidence for benefit. This reveal has been postponed until the coming year.

In place of the top vaccines chief, Tracy Beth Høeg is scheduled to present at the event. She was just designated acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this calendar year.

A New Direction at the Agency

Høeg's temporary position could signify a tighter collaboration between the drug and vaccine divisions as Dr. Høeg and Prasad solidify control at the FDA – and it signals a increased emphasis upon rolling back already-approved immunizations at the FDA.

The new acting director has often pushed for discontinuing some childhood vaccine recommendations in the US in order to be more like the Danish model, a society with nationalized medicine and a population roughly the population of Wisconsin’s.

To date statements, she has kept her attention on vaccines – usually the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Concerns Over Qualifications

The appointee has no apparent background in pharmaceutical research, oversight or management, which has been typical for former heads of the biologics center. She has worked at the FDA as a top consultant to the agency head and CBER since earlier this year.

“She appears not to have any of the qualifications” for running the drug-regulation department, remarked Jonathan Howard. “She’s never run a scientific study. She is not versed in running a major agency. She lacks background in drug approvals.”

Previous commissioners of the center would “be deeply familiar with regulatory frameworks and the research of medication creation”, said Dr. Janet Woodcock. “Frankly, she lacks the sort of resume that former directors who headed CBER have had.”

This division has an enormous portfolio at the agency, Woodcock emphasized.

“Many people just pays attention on the new drug program, but the generic program approves a multitude of off-brand pharmaceuticals. There’s a biosimilars program, non-prescription drug unit and other areas, and each of these have to be supervised,” Woodcock explained. “The responsibility you overlook, that is precisely what that I always told people is going to cause problems.”

Furthermore, a substantial leadership aspect to the job, which manages over 5,000 staff members. “It is a huge leadership role, if you perform it correctly,” the former official said.

Agency Reaction and Contentious Programs

When asked about questions about Høeg’s credentials and whether this assignment represents more teamwork among regulatory chiefs on immunizations, a spokesperson stated that the “concerns rely on inaccurate assumptions”.

“Her experience is consistent with the duties of her job,” the official explained, pointing to the months Høeg spent advising the FDA commissioner on “medication safety and oversight research, including computational safety modeling and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the commissioner’s recently launched priority voucher program, a contentious one-day therapy clearance system that apparently concerned her predecessors. “How are these drugs being picked for this expedited pathway? Who takes the decisions?” Howard asked. “There is a lot of secrecy happening at the agency right now.”

Overall, he remarked, “the FDA seems to be moving towards less stringent rules of all drugs, except for vaccines.”

Documented History on Immunizations

Regarding vaccines, Dr. Høeg has a more established, if problematic, track record, critics said. She authored a research paper using unverified crowd-sourced reports to determine the rate of myocarditis following COVID-19 vaccination. She consulted for the Florida top health official Joseph Ladapo, who reportedly have altered data to imply COVID-19 vaccinations are pose a greater threat than they are.

Part of her “wish list” for the incoming federal leadership featured changing rules for novel immunizations and halting “non-essential” vaccines, she stated after the election on a online show. At the agency, Dr. Høeg has reportedly floated the idea of barring adolescent males from getting COVID-19 vaccinations.

“She’s an thorough dogmatist who commences with her preconceived notions and works backwards to retrofit the science in a very disingenuous, fraudulent fashion,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Høeg aligned with other skeptics, {like|